Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
A questionnaire study was performed to determine the current status of palivizumab prophylaxis against respiratory syncytial virus infection in Japanese children with congenital heart disease <2 years of age. Palivizumab prophylaxis decreased the respiratory syncytial virus hospitalization rate by 42.8%.
Saji
Tsutomu
T
Division of Pediatric Cardiology, Department of Pediatrics, Faculty of Medicine, Toho University Medical Center, Omori Hospital, 6-11-1 Omori-nishi, Ota-ku, Tokyo, Japan. bentsaji@med.toho-u.ac.jp
Nakazawa
Makoto
M
Harada
Kensuke
K
D019072:Antibiotic Prophylaxis; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D006306:Health Surveys; D006330:Heart Defects, Congenital / Q000150:complications* / Q000821:virology; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007564:Japan / Q000453:epidemiology; D008297:Male; D000069455:Palivizumab; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000379:methods; D018357:Respiratory Syncytial Virus Infections / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D018113:Respiratory Syncytial Virus, Human / Q000276:immunology; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab